Description IGF-1 LR3 (Long [Arg] Insulin-like Growth Factor-1) is a recombinant synthetic analog of human insulin-like growth factor 1, engineered with two structural modifications: an arginine substitution replacing glutamate at position 3 of the IGF-1 sequence (reducing IGFBP-3 binding affinity), and a 13-amino-acid N-terminal extension (Long peptide leader)
In addition corticosteroids have been associated with local skin atrophy, depigmentation and muscle wasting, resulting in an increase in the bony prominence of the medial epicondyle
There are a number of reasons for this, with the most prominent being the need to treat chronic pain after developing diabetic neuropathy (pain resulting from nerve damage) as a side effect of insulin resistance
Emerging research highlights a paradoxical relationship between probiotic use and cognitive symptoms such as brain fog, revealing the gut-brain axiss complex interplay [86, 130, 131]
(PubMed) Zhang X, Liang D, Guo L, et al
Despite the lack of evidence for direct A or tau clearance/lowering, the observed metabolic benefits of GLP-1, both peripheral and central, indicate a promising direction for further exploration
